Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02051218
Recruitment Status : Active, not recruiting
First Posted : January 31, 2014
Last Update Posted : June 9, 2021
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2022